reason report
tripl pivot trial short sweet launch
bottom line vertex announc yesterday market close
initi first four phase tripl combin
studi time month ahead prior expect
even importantli trial shorter
compani prior pivot studi cf combin fda
agre singl pivot trial high unmet need het-min
cf popul primari efficaci endpoint
week safeti endpoint week extend blind
follow secondari endpoint follow convers
manag clear first tripl trial enrol
quickli believ regulatori submiss could
occur earli half base updat
acceler launch time tripl combin one
quarter previous ad tripl
combin revenu het/min popul model
updat chang price target
maintain outperform rate vertex stock
average ep rev
disc dcf wacc
tg
net debt total capit
price-to-earnings lt ep growth
compani inform leerink partner llc research
revenu million
pleas refer page import disclosur price chart analyst certif
price target vertex rate stock outperform thesi
base expect continu captur cystic fibrosi cf patient subpopul
vertex success iter cf modul oral combin medicin expect
vertex cf revenu line grow steadili
probabl success tripl combin valuat account
full expect valu cf portfolio consid competitor forecast
valuat believ develop path time market challeng vertex
well posit partner acquir show promis flirt profit
past vertex seem determin maintain recent recov profit appear
capabl grow oper margin end
beyond compani still aspir discov develop drug categori larg
diversifi invest associ expens risk thesi valuat howev
potenti sizabl near-term growth stock offer strong valuat upsid potenti
next month
first four pivot studi begin come day vertex plan conduct four
phase tripl combin studi select combin
studi underserv het/min popul two
larger homozyg popul design support regulatori file
clear het-min indic proceed ahead indic
file approv sooner acceler regulatori timelin vertex announc
yesterday first het/min studi tripl enrol subject around
world ex-franc begin within day post clinic trial websit later
today patient studi requir least year old singl
mutat plu one hundr minim function mutat enrol subject
receiv either placebo week prior control arm switch
activ drug open label basi primari endpoint studi mean
absolut chang lung function baselin week four fda requir
week safeti data addit primari efficaci analysi new drug
applic nda secondari endpoint includ pulmonari exacerb chang bodi
mass index chang sweat chlorid chang cystic fibrosi questionnair score
measur week requir submiss
time durat trial size better expect view
phase studi requir first tripl combin posit base shorter-
than-expect durat rel small patient enrol requir prior
develop previou convers manag expect fda requir
month safeti data regulatori submiss base case scenario spoke
member vertex manag team follow press releas yesterday even
indic high unmet need het/min popul addit promis exist
tripl combin data led flexibl regulatori requir indic vertex
suggest enrol studi take place quickli given estim
het/min patient us age without exist treatment compani
expect patient recruit begin within day state gate factor complet
enrol like time take get variou site on-line around world oppos
launch seem feasibl base updat believ tripl combin
regimen could launch versu previou expect believ
averag enrol rate conserv given previou cf studi
vertex medicin would result full enrol mid vertex studi
inferior medicin orkambi less medic urgenc enrol mani
patient per month time potenti conserv consid week safeti
need regulatori submiss plausibl nda file would occur
given applic breakthrough therapi design seem certain receiv
prioriti review tezacaftor ivacaftor alreadi approv acceler review cycl
time seem highli like trial duplic recent disclos phase ii result timelin
would result acceler approv indic late next year convers
vertex manag team reiter full data requir
approv suggest approv occur prior complet studi
find variou secondari endpoint could ad label later time vertex
indic expect trial design upcom studi homozyg
popul due less urgent medic need compani also suggest
discuss second tripl combin still on-going regul
offer updat guidanc previou time begin studi
chang model account earlier expect approv het/min popul
like increment revenu given current label indic
due earlier-than-expect trial start well shorten time requir
regulatori file adjust model reflect tripl combin launch het/min
popul versu previous result chang
increas revenu forecast correspond increas
pro forma dilut ep estim year updat revenu forecast vertex
pro forma ep revenu forecast recent consensu
estim ep forecast recent consensu made
chang model price target remain reiter outperform
rate
price target vertex base simpl averag three approach
believ reason basi valu stock today approach simpl price
earn multipl high growth larg cap biopharmaceut compani price sale multipl
mid larg cap high growth biopharmaceut compani discount cash flow dcf
use current averag high growth larg cap biopharma multipl ep
nvo appli current ep estim discount
back year compani cost equiti give valu one year use
averag high growth larg cap biotech price-to-revenu multipl sale
nvo appli revenu estim post-tripl
discount back year compani cost equiti give valu one year
lastli dcf valuat given wacc termin cash flow growth rate give
present valu averag three method current price target
risk view outlook valuat vertex includ major chang price
reimburs coverag label competit posit kalydeco orkambi
compani main product today major risk disappoint delay failur
compani develop regulatori file second first gener cf corrector
tezacaftor compani much-anticip dual corrector/potenti tripl combin
program risk includ acceler success develop altern modul
cftr altern approach treat cf gene therapi final compani
histori spend much potenti earn expens diversifi acquisit could
undermin futur expect valu compani cf portfolio opportun better-than
expect perform includ realiz signific revenu compani current cf
dual combin market outsid us well acceler clinic develop
leerink partner research compani file zack factset consensu
leerink partner research compani file zack factset consensu
million
product sale po adjust
tripl combin kalydeco second corrector full year sale
total product sale book
product sale po adjust
total product sale book
leerink partner research compani file
million
product sale direct product sale vertex
sale
 total revenu
sg total revenu
leerink partner research compani file
analysi stock price leerink target
method large-cap healthcar ep multipl lp normal earn
current averag high growth larg cap high growth biopharma multipl ep
leerink ep
impli price ep use current consensu high growth larg cap multipl
equiti
number period
impli one year target price approach
method discount futur valu normal revenu use mid larg cap biotech compar
averag growth larg cap mid cap biotech price-to-revenu multipl sale
impli vertex enterpris valu sale estimate mm
estimate net
impli vertex equiti valu mm
equiti
number period
impli vertex valu mm
impli one year target price approach
method dcf base current product po adjust outlook cf franchis use wacc
present valu late stage market product flow
net debt end
averag method
leerink partner research compani file factset
